Glenmark Pharmaceuticals is reportedly planning to launch its first biotechnology medicine in the US or Europe by 2017. A biologic remedy for ulcerative colitis is progressing through US trials after being licensed to Paris-based Sanofi and may come to market from 2017 to 2020.
Further, the company is on track to grow sales about 20% in the 12 months through March 2014.
Glenmark’s current portfolio consists of 90 products authorized for distribution in the US marketplace and 53 ANDA’s pending approval with the USFDA. In addition to these internal Filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.
Further, the company is on track to grow sales about 20% in the 12 months through March 2014.
Glenmark’s current portfolio consists of 90 products authorized for distribution in the US marketplace and 53 ANDA’s pending approval with the USFDA. In addition to these internal Filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.
No comments:
Post a Comment